Literature DB >> 2459808

Immunochemical and structural similarities in toxin A and toxin B of Clostridium difficile shown by binding to monoclonal antibodies.

S W Rothman1, M K Gentry, J E Brown, D A Foret, M J Stone, M P Strickler.   

Abstract

Clostridium difficile toxins A and B were shown to share immunochemical and structural features, including shared sequential epitopes. Nineteen hybridomas generated after immunization of mice with a mixture of toxoids produced monoclonal antibodies, all IgM(x), which bound to toxin A and toxin B in a solid-phase radioimmunoassay (RIA). None of the antibodies neutralized the cytotoxicity of either toxin, alone or in pairs, nor did they neutralize mouse lethality. The antibodies did not inhibit hemagglutination by toxin A, and none of those tested neutralized the toxin's enterotoxic activity. Studies of binding of antibodies to native toxins in the RIA showed that the antibodies differed in their recognition of the toxins. Many of the antibodies bound with higher avidity to toxin A than to toxin B. In Western blots, all the antibodies recognized both toxins in the native state; in addition, some antibodies recognized the minor cytotoxic species of toxin B. When the toxins were denatured and reduced, five antibodies bound to both toxins, five to A only, and nine to neither, demonstrating that the antibodies had different epitope specificities. Further structural comparisons were made by investigation of mol. wts, subunit structures and amino acid compositions. The native mol. wts of toxin A and toxin B, as determined by electrophoresis to equilibrium in 4-30% polyacrylamide gel electrophoresis (PAGE), were 430,000 and 368,000, respectively. Denatured and reduced toxins each had a single subunit of 315,000. Both toxins had about 50% hydrophobic amino acids.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2459808     DOI: 10.1016/0041-0101(88)90239-5

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  7 in total

1.  Development and evaluation of an ovine antibody-based platform for treatment of Clostridium difficile infection.

Authors:  April Roberts; Joanna McGlashan; Ibrahim Al-Abdulla; Roger Ling; Harriet Denton; Steve Green; Ruth Coxon; John Landon; Clifford Shone
Journal:  Infect Immun       Date:  2011-12-05       Impact factor: 3.441

2.  Monoclonal antibodies specific for Clostridium difficile toxin B and their use in immunoassays.

Authors:  F Müller; C Stiegler; U Hadding
Journal:  J Clin Microbiol       Date:  1992-06       Impact factor: 5.948

Review 3.  Toxigenic clostridia.

Authors:  C L Hatheway
Journal:  Clin Microbiol Rev       Date:  1990-01       Impact factor: 26.132

4.  Nonspecific binding of Clostridium difficile toxin A to murine immunoglobulins occurs via the fab component.

Authors:  D L Cooke; S P Borriello
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

5.  Cloning of Clostridium difficile toxin B gene and demonstration of high N-terminal homology between toxin A and B.

Authors:  C von Eichel-Streiber; R Laufenberg-Feldmann; S Sartingen; J Schulze; M Sauerborn
Journal:  Med Microbiol Immunol       Date:  1990       Impact factor: 3.402

6.  Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A.

Authors:  G Corthier; M C Muller; T D Wilkins; D Lyerly; R L'Haridon
Journal:  Infect Immun       Date:  1991-03       Impact factor: 3.441

7.  Interrelationships between digestive proteolytic activities and production and quantitation of toxins in pseudomembranous colitis induced by Clostridium difficile in gnotobiotic mice.

Authors:  G Corthier; M C Muller; G W Elmer; F Lucas; F Dubos-Ramaré
Journal:  Infect Immun       Date:  1989-12       Impact factor: 3.441

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.